Research and Development, Sequenom Center for Molecular Medicine, San Diego, CA, USA.
PLoS One. 2013;8(3):e57381. doi: 10.1371/journal.pone.0057381. Epub 2013 Mar 6.
Circulating cell-free (ccf) fetal DNA comprises 3-20% of all the cell-free DNA present in maternal plasma. Numerous research and clinical studies have described the analysis of ccf DNA using next generation sequencing for the detection of fetal aneuploidies with high sensitivity and specificity. We sought to extend the utility of this approach by assessing semi-automated library preparation, higher sample multiplexing during sequencing, and improved bioinformatic tools to enable a higher throughput, more efficient assay while maintaining or improving clinical performance.
Whole blood (10mL) was collected from pregnant female donors and plasma separated using centrifugation. Ccf DNA was extracted using column-based methods. Libraries were prepared using an optimized semi-automated library preparation method and sequenced on an Illumina HiSeq2000 sequencer in a 12-plex format. Z-scores were calculated for affected chromosomes using a robust method after normalization and genomic segment filtering. Classification was based upon a standard normal transformed cutoff value of z = 3 for chromosome 21 and z = 3.95 for chromosomes 18 and 13.
Two parallel assay development studies using a total of more than 1900 ccf DNA samples were performed to evaluate the technical feasibility of automating library preparation and increasing the sample multiplexing level. These processes were subsequently combined and a study of 1587 samples was completed to verify the stability of the process-optimized assay. Finally, an unblinded clinical evaluation of 1269 euploid and aneuploid samples utilizing this high-throughput assay coupled to improved bioinformatic procedures was performed. We were able to correctly detect all aneuploid cases with extremely low false positive rates of 0.09%, <0.01%, and 0.08% for trisomies 21, 18, and 13, respectively.
These data suggest that the developed laboratory methods in concert with improved bioinformatic approaches enable higher sample throughput while maintaining high classification accuracy.
循环无细胞(ccf)胎儿 DNA 占母体血浆中所有无细胞 DNA 的 3-20%。大量的研究和临床研究已经描述了使用下一代测序分析 ccf DNA,以高灵敏度和特异性检测胎儿非整倍体。我们试图通过评估半自动文库制备、测序时更高的样本多重化以及改进的生物信息学工具来扩展这种方法的用途,从而实现更高的通量、更有效的检测,同时保持或提高临床性能。
从孕妇捐献者采集 10mL 全血,并使用离心法分离血浆。使用基于柱的方法提取 ccf DNA。文库使用优化的半自动文库制备方法进行制备,并在 Illumina HiSeq2000 测序仪上以 12 重格式进行测序。在归一化和基因组片段过滤后,使用稳健的方法计算受影响染色体的 Z 分数。分类基于标准正态转换的截断值 z = 3 用于 21 号染色体,z = 3.95 用于 18 号和 13 号染色体。
使用总共超过 1900 个 ccf DNA 样本进行了两项平行的检测开发研究,以评估自动化文库制备和增加样本多重化水平的技术可行性。这些过程随后被结合起来,并完成了对 1587 个样本的研究,以验证过程优化检测的稳定性。最后,对利用这种高通量检测与改进的生物信息学程序相结合的 1269 个正常和非整倍体样本进行了非盲临床评估。我们能够正确检测到所有的非整倍体病例,其假阳性率极低,分别为 21 三体、18 三体和 13 三体的 0.09%、<0.01%和 0.08%。
这些数据表明,与改进的生物信息学方法相结合的开发实验室方法能够提高样本通量,同时保持高分类准确性。